TRENDFINDERS- Scanning Board for Charts and Stocks

[peewee]

Among biotech stocks, British minnow Antisoma (ASM.L), whose stock plunged 70 percent in March when a lung cancer drug it was developing with Novartis failed in a Phase III trial, saw a partial revival in its fortunes on hopes for other drugs in earlier-stage development.

Shares in Antisoma, which presented updates on both AS1413 and AS1411 at ASCO, rose 21 percent. (Reporting by Ben Hirschler in London and Lewis Krauskopf in New York; Editing by Karen Foster and Maureen Bavdek)

http://www.reuters.com/article/idCNN0714001720100607?rpc=44